The use of agonistic anti-CD40 therapy in treatments for cancer

International Reviews of Immunology

Volumn 31, Issue 4, 2012, Pages 246-266

  Khong, Andrea ^a   Nelson, Delia J ^b   Nowak, Anna K ^a,c,d   Lake, Richard A ^a,c   Robinson, Bruce W S ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c National Centre for Asbestos Related Diseases   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Agonistic anti CD40; Cancer; Immunotherapy; Mesothelioma

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD40 ANTIGEN; CISPLATIN; CP 870893; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DOXORUBICIN; GEMCITABINE; IMIQUIMOD; INTERLEUKIN 2; INTERLEUKIN 5; LUCATUMUMAB; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY CD40; MONOCLONAL ANTIBODY CTLA4; MONOCLONAL ANTIBODY DR5; PACLITAXEL; PEMETREXED; PETHIDINE; RECOMBINANT HUMAN CD40 LIGAND; RITUXIMAB; TICILIMUMAB; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARCINOMA; CD8+ T LYMPHOCYTE; CELL THERAPY; CHILL; COLON CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ENDOTHELIUM CELL; FEVER; FIBROSARCOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOMA; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RIGOR; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84863924198     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.698338     Document Type: Article

References (124)

1. Yellin MJ, et al. Functional interactions of T cells with endothelial cells: The role of CD40L-CD40- mediated signals. J ExpMed. 1995;182(6):1857- 1864.
2. Chiodoni C, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203(11):2441-2450. (Pubitemid 44664614)
3. Hamzah J, et al. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest. 2008;118(5):1691-1699. (Pubitemid 351632373)
4. Banchereau J, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922. (Pubitemid 24140434)
5. Law CL, Grewal IS.Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. Adv ExpMed Biol. 2009;647:8-36.
6. Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch ImmunolTher Exp (Warsz). 1999;47(2):83-88.
7. Restifo NP, et al.Molecularmechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol. 1993;14(3):182-190. (Pubitemid 23319206)
8. Gajewski TF, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:. 131-145. (Pubitemid 44401498)
9. Jackaman C, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol. 2003;171(10):5051-5063. (Pubitemid 37432786)
10. Jackaman C, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008;20(11):1467-1479.
11. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29(3):372-383.
12. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008;20(1):89-95.
13. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010;10(6):403-414.
14. McDonnell AM, Robinson BW,Currie AJ. Tumor antigen cross-presentation and the dendritic cell: Where it all begins? Clin Dev Immunol. 2010;Article ID 539519, 9 pages, 2010.
15. Ghiringhelli F, et al. Tumor cells convertimmaturemyeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J ExpMed. 2005;202(7):919-929. (Pubitemid 41396892)
16. GabrilovichD.Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941-952. (Pubitemid 39620069)
17. Kurts C, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A. 1999;96(22):12703-12707. (Pubitemid 29513566)
18. Marzo AL, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165(11):6047-6055.
19. Sparso T, et al.The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia. 2008;51(1):70-75. (Pubitemid 50003447)
20. Burgdorf C, Schunkert H, Kurowski V. Is concomitant coronary artery disease an exclusion criterion for transient left ventricular apical ballooning? Int J Cardiol. 2008;125(1):e8-e9. (Pubitemid 351305394)
21. Grohmann U, et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol. 2001;166(1):277-283. (Pubitemid 32038443)
22. Hunter TB, et al. An agonist antibody specific for CD40 induces dendritic cellmaturation and promotes autologous anti-tumour T-cell responses inaninvitro mixed autologous tumourcell/lymph node cell model. Scand J Immunol. 2007;65(5):479-486. (Pubitemid 46632548)
23. Ridge JP, Di Rosa F,Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393(6684):474-478.
24. Cella M, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747-752. (Pubitemid 26324129)
25. Toes RE, et al. CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol. 1998;10(6):443-448. (Pubitemid 28564373)
26. Schoenberger SP, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480-483.
27. French RR, et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. NatMed. 1999;5(5):548-553. (Pubitemid 29220214)
28. Jackaman C, Nelson DJ. Intratumoral interleukin-2/agonist CD40 antibody drives CD4(+)- independent resolution of treated-tumors and CD4(+)-dependent systemic and memory responses. Cancer Immunol Immunother. 2012;61:549-560.
29. Bourgeois C, et al. CD8 lethargy in the absence of CD4 help. Eur J Immunol. 2002;32(8):2199-2207. (Pubitemid 34965882)
30. Nagy JA, et al.Why are tumour blood vessels abnormal andwhy is it important to know?Br JCancer. 2009;100(6):865-869.
31. vanMierlo GJ, et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol. 2004;173(11):6753-6759. (Pubitemid 39541061)
32. Todryk SM, et al. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 2001;248(1-2):139-147. (Pubitemid 32167031)
33. Marzo AL, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol. 1999;162(10):5838-5845. (Pubitemid 29314936)
34. Stumbles PA, et al. Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol. 2004;173(10):5923- 5928. (Pubitemid 39487745)
35. den Haan JM, BevanMJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J ExpMed. 2002;196(6):817-827.
36. Moron G, et al. CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med. 2002;195(10):1233-1245. (Pubitemid 34564326)
37. Pooley JL, Heath WR, Shortman K. Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. 2001;166(9):5327-5330. (Pubitemid 32374150)
38. Ruter J, et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10(10):983-993.
39. Backer R, et al. CD8- dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens. Eur J Immunol. 2008;38(2):370-380.
40. Ballesteros-Tato A, et al. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat Immunol. 2010;11(3):216-224.
41. Bedoui S, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10(5):488-495.
42. del Rio ML, et al. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J Immunol. 2007;178(11): P. 6861-6866.
43. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol. 2008;181(1):155-164.
44. McDonnell AM, et al. CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens froma solid tumor. Eur J Immunol. 2010;40(6):1617-1627.
45. Lee BO, et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol. 2003;171(11):5707-5717. (Pubitemid 37467185)
46. Buhmann R, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93(6):1992-2002. (Pubitemid 29128502)
47. Lapointe R, et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63(11):2836-2843. (Pubitemid 36667155)
48. Coughlin CM, et al. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: Implications for pediatric immunotherapy. Blood. 2004;103(6):2046-2054. (Pubitemid 38326219)
49. Kim SK, et al. Induction ofmyeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded withmyeloma tumor antigens. Ann Hematol. 2009;88(11):1113-1123.
50. Gordon J, et al. Anti-tumor immunity in B-lymphocyte-deprived mice, III: Immunity to primary Moloney sarcoma virus-induced tumors. Int J Cancer. 1982;29(3):351-357. (Pubitemid 12141242)
51. Schultz KR, et al.The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science. 1990;249(4971):921-923.
52. DiLillo DJ, K. Yanaba, Tedder TF B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006-4016.
53. Qin Z, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4(5):627-630. (Pubitemid 28237366)
54. Jackaman C, et al. CD40-activated B cells contribute tomesothelioma tumor regression. Immunol Cell Biol. 2011;89(2):255-267.
55. Carpenter EL, et al. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous Toll-like receptor 9 stimulation. J TranslMed. 2009;7:93.
56. Perricone MA, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother. 2004;27(4):273-281. (Pubitemid 38833323)
57. ClatworthyMR,et al. B-cell-depleting induction therapy and acute cellular rejection.NEngl JMed. 2009;360(25):2683-2685.
58. Kondo E, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol. 2002;169(4):2164-2171. (Pubitemid 34857684)
59. Schultze JL, et al. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100(11):2757-2765. (Pubitemid 28007544)
60. von Bergwelt-Baildon MS, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application. Blood. 2002;99(9):3319-3325.
61. von Bergwelt-Baildon M, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: Potential as cellular adjuvants. Blood. 2006;107(7):2786-2789.
62. Murugaiyan G,Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 2007;28(11):467-473. (Pubitemid 350103683)
63. Garbi N, et al. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004;172(10):5861-5869. (Pubitemid 38621184)
64. Tong AW, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma. 2000;36(5-6):543-558. (Pubitemid 30103180)
65. Restifo NP, et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177(2):265-272. (Pubitemid 23117076)
66. Kikuchi T, Crystal RG, Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10(8):1375-1387. (Pubitemid 29267591)
67. Kikuchi T, et al. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res. 2000;60(22):6391-6395.
68. Friedlander PL, et al. Efficacy ofCD40 ligand gene therapy inmalignantmesothelioma.AmJRespir CellMol Biol. 2003;29(3 Pt 1):321-330. (Pubitemid 37093990)
69. Andersen NS, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primarymantle cell lymphoma cell cultures. Blood. 2000;96(6):2219-2225.
70. Challa A, et al. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood. 2002;99(9):3411-3418. (Pubitemid 34525324)
71. Buhtoiarov IN, et al. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005;174(10):6013-6022. (Pubitemid 40663788)
72. LumHD, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006;79(6):1181-1192.
73. Buhtoiarov IN, et al. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol. 2006;176(1):309-318. (Pubitemid 43023276)
74. LumHD, et al. Tumoristatic effects of anti-CD40 mAb-activatedmacrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 2006;118(2):261-270.
75. Turner JG, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells. J Immunol. 2001;166(1):89-94. (Pubitemid 32038420)
76. Zhang M, et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A. 2009;106(18):7513-7518.
77. Jackaman C, et al. IL-2/CD40-driven NK cells install and maintain potency in the antimesothelioma effector/memory phase. Int Immunol. 2012;24(6):357-68.
78. Fransen MF, et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270-2280.
79. Gladue RP, et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011;60(7):1009-1017.
80. Vonderheide RH, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonistmonoclonal antibody. J Clin Oncol. 2007;25(7):876-883. (Pubitemid 350002889)
81. Broomfield S, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 2005;65(17):7580-7584. (Pubitemid 41297228)
82. Broomfield SA, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009;182(9):5217-5224.
83. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of establishedmurine solid tumors. Cancer Res. 2003;63(15):4490-4496. (Pubitemid 36951021)
84. Houtenbos I, et al. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity. Br J Haematol. 2008;142(2):273-283. (Pubitemid 351987304)
85. Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011;32(22):5134-5147.
86. Murphy WJ, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol. 2003;170(5):2727-2733. (Pubitemid 36245667)
87. Berner V, et al. IFN-gamma mediatesCD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. NatMed. 2007;13(3):354-360. (Pubitemid 46376686)
88. Alderson KL, et al. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol. 2008;180(5):2981-2988.
89. Weiss JM, et al. Successfulimmunotherapywith IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009;106(46):19455-19460.
90. Currie AJ, et al. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol. 2008;180(3):1535-1544.
91. Ahonen CL, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008;111(6):3116-3125.
92. Ahonen CL, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J ExpMed. 2004;199(6):775-784. (Pubitemid 38375197)
93. Sorensen MR, et al. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine. 2010;28(41):6757-6764.
94. Uno T, et al. Eradication of established tumors in mice by a combination antibody-based therapy. NatMed. 2006;12(6):693-698. (Pubitemid 43865240)
95. Westwood JA, et al. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer inmice. J TranslMed. 2010;8:42.
96. Christiansen AJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A. 2011;108(10):4141-4146.
97. Liu C, et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012;35(3):276-282.
98. ChoHI, et al. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 2012;72(8):1986-1995.
99. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972. 26(4):239-257.
100. Zitvogel L, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73.
101. Nowak AK, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170(10):4905-4913. (Pubitemid 36554719)
102. Beatty GL, et al. CD40 agonists alter tumor stroma and showefficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612- 1616.
103. Buhtoiarov IN, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpGODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226-239.
104. Johnson EE, et al. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40mAb and CpG in mice. J Immunother. 2011;34(1):76-84.
105. Vonderheide RH, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19(13):3280-3287.
106. Kalbasi A, et al. Prevention of interleukin-2withdrawal-induced apoptosis in lymphocytes retrovirally cotransducedwith genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother. 2010;33(7):672-683.
107. Drabick JJ, Schell TD. Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther. 2010;10(10):994-996.
108. Forero-Torres NLB, et al. A Phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: Multiple responses observed in patients with relapsed diffuse large B-cell lymphoma. In ASH AnnualMeeting Abstracts. 2009. Blood. Conference abstract; Paper # 586.
109. Burington B, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci TranslMed. 2011. 3(74):74ra22.
110. Cella M., et al. Maturation, activation, and protection of dendritic cells induced by doublestranded RNA. J ExpMed. 1999;189(5):821-829. (Pubitemid 29189687)
111. Robinson RA, et al. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst. 1976;57(3):599-602.
112. Nicodemus CF, et al. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010;202(6):608 e1-e8.
113. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161-167.
114. Jahrsdorfer B,Weiner GJ.CpGoligodeoxynucleotides asimmunotherapy in cancer.UpdateCancer Ther. 2008;3(1):27-32.
115. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: Emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293-307.
116. Singh SK, et al.Design of neo-glycoconjugates that target themannose receptor and enhance TLRindependent cross-presentation and Th1 polarization. Eur J Immunol. 2011;41(4):916-925.
117. GhoshM, et al. CD13 regulates dendritic cell cross-presentation and T cell responses by inhibiting receptor-mediated antigen uptake. J Immunol. 2012.
118. Hermans IF, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171(10):5140-5147. (Pubitemid 37432797)
119. Kitamura H., et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J ExpMed. 1999;189(7):1121-1128.
120. Castellino F, et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440(7086):890-895.
121. Semmling V, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol. 2010;11(4):313-320.
122. Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti- CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine. 2010;28(5):1383-1390.
123. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333(6045):1030-1034.
124. White AL, et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011;187(4):1754-1763.